Enrique Galve1, Alberto Cordero2, Angel Cequier3, Emilio Ruiz4, José Ramón González-Juanatey5. 1. Servicio de Cardiología, Hospital General Universitario Vall d'Hebron, Barcelona, Spain. Electronic address: egalve@vhebron.net. 2. Departamento de Cardiología, Hospital de San Juan, San Juan de Alicante, Alicante, Spain. 3. Servicio de Cardiología, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. 4. Ferrer Internacional, Barcelona, Spain. 5. Departamento de Cardiología, Complejo Hospitalario Universitario, Santiago de Compostela, A Coruña, Spain.
Abstract
INTRODUCTION AND OBJECTIVES: Lipid control is insufficient in patients with coronary heart disease but this situation may be improving with the implementation of the latest clinical practice guidelines. The aim of this study was to analyze whether target values of low-density lipoprotein cholesterol are achieved and to identify associated factors and physicians' attitudes to deficient control. METHODS: We conducted a national, multicenter, prospective, observational study of 1103 patients with stable coronary heart disease, analyzing lipid values and a broad set of clinical variables. The statistical analysis involved a binary logistic regression model using backward stepwise elimination. RESULTS: Low-density lipoprotein cholesterol was < 70 mg/dL in only 26% of patients, even though 95.3% were receiving cholesterol-lowering agents, 45% of which were high-intensity therapies. Independent predictors of low-density lipoprotein cholesterol < 70 mg/dL were diabetes mellitus, wholegrain bread, shorter history of dyslipidemia, and, especially, high-intensity cholesterol-lowering therapies. Physicians increased therapy in only 26% of poorly controlled patients. The main predictor of increased therapy was low-intensity baseline therapy (odds ratio=5.05; 95% confidence interval, 3.3-9.2). A more proactive approach was observed in older physicians (P=.019) and longer physician practice (P=.02). CONCLUSIONS: Despite the new guidelines, only 26% of patients with coronary heart disease have adequate lipid control. In 70% of patients, physicians continue the same therapy, even though high-intensity cholesterol-lowering therapies are a key factor in good control.
INTRODUCTION AND OBJECTIVES:Lipid control is insufficient in patients with coronary heart disease but this situation may be improving with the implementation of the latest clinical practice guidelines. The aim of this study was to analyze whether target values of low-density lipoprotein cholesterol are achieved and to identify associated factors and physicians' attitudes to deficient control. METHODS: We conducted a national, multicenter, prospective, observational study of 1103 patients with stable coronary heart disease, analyzing lipid values and a broad set of clinical variables. The statistical analysis involved a binary logistic regression model using backward stepwise elimination. RESULTS: Low-density lipoprotein cholesterol was < 70 mg/dL in only 26% of patients, even though 95.3% were receiving cholesterol-lowering agents, 45% of which were high-intensity therapies. Independent predictors of low-density lipoprotein cholesterol < 70 mg/dL were diabetes mellitus, wholegrain bread, shorter history of dyslipidemia, and, especially, high-intensity cholesterol-lowering therapies. Physicians increased therapy in only 26% of poorly controlled patients. The main predictor of increased therapy was low-intensity baseline therapy (odds ratio=5.05; 95% confidence interval, 3.3-9.2). A more proactive approach was observed in older physicians (P=.019) and longer physician practice (P=.02). CONCLUSIONS: Despite the new guidelines, only 26% of patients with coronary heart disease have adequate lipid control. In 70% of patients, physicians continue the same therapy, even though high-intensity cholesterol-lowering therapies are a key factor in good control.
Authors: Vivencio Barrios; Carlos Escobar; Carmen Suarez; Xavier Garcia-Moll; Francisco Lozano Journal: J Clin Med Date: 2022-06-20 Impact factor: 4.964
Authors: Jose Javier Gomez-Barrado; Paula Gomez-Turegano; Carolina Ortiz-Cortes; Jorge Vega-Fernandez; Marta Gomez-Turegano; Francisco Javier Garciperez de Vargas; Luis Enrique Lezcano Gort; Zineb Kounka; Benjamin Roque Rodriguez; David Chipayo Gonzales; Paloma Perez-Espejo; Ana Isabel Fernandez-Chamorro; Maria Beltran Moreno; Maria Jose Romero Castro; Maria Victoria Mogollon Jimenez; Gonzalo Marcos Gomez; Yolanda Porras Ramos Journal: Cardiol Res Date: 2020-08-01
Authors: Alberto Cordero; Moisés Rodríguez-Mañero; Lorenzo Fácila; M Rosa Fernández-Olmo; Manuel J Gómez-Martínez; Alfonso Valle; Jose Mª Castellano; Miriam Martín Toro; José Seijas-Amigo; Alvaro Vicedo; José R González-Juanatey Journal: J Diabetes Metab Disord Date: 2020-06-01
Authors: Ricardo Lopez Santi; Felipe Martinez; Adrian Baranchuk; Alvaro Sosa Liprandi; Daniel Piskorz; Alberto Lorenzatti; Maria Pilar Lopez Santi; Juan Carlos Kaski Journal: Eur Cardiol Date: 2021-04-27
Authors: Emma Forcadell Drago; Maria Rosa Dalmau Llorca; Carina Aguilar Martín; Ignacio Ferreira-González; Zojaina Hernández Rojas; Alessandra Queiroga Gonçalves; Carlos López-Pablo Journal: Int J Environ Res Public Health Date: 2020-11-19 Impact factor: 3.390
Authors: Jose Seijas-Amigo; Mónica Gayoso-Rey; María José Mauriz-Montero; Pedro Suarez-Artime; Antonia Casas-Martinez; María Dominguez-Guerra; Lara Gonzalez-Freire; Ana Estany-Gestal; Alberto Codero-Fort; Moisés Rodriguez-Mañero; Jose Ramón Gonzalez-Juanatey Journal: Clin Investig Arterioscler Date: 2022-02-03